Submission of unaudited standalone & consolidated financial results for the quarter & nine month ended 31.12.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medi-Caps Limited has filed its Q3 FY26 (quarter ended December 31, 2025) and nine-month unaudited results along with limited review reports from statutory auditor Rawka & Associates, who gave an unmodified opinion. On a standalone basis, revenue from operations jumped to Rs. 77.28 lakhs in Q3 from Rs. 25.28 lakhs a year ago, driven by sale of shops at Medi-caps Business Park, helping the company swing back to a profit of Rs. 28.50 lakhs versus Rs. 26.47 lakhs last year. On a consolidated basis, Q3 revenue rose modestly to Rs. 425.31 lakhs from Rs. 400.91 lakhs, but nine-month revenue fell sharply to Rs. 899.71 lakhs from Rs. 1,843.93 lakhs. Consolidated net loss widened to Rs. -607.93 lakhs for the nine months (vs Rs. -228.92 lakhs), mainly dragged by wholly-owned subsidiary Medgel Private Limited which posted a loss of Rs. -625.35 lakhs. The pharma division remains the larger segment by revenue, while the real estate division is the small but growing piece.
Standalone shows a clear turnaround thanks to real estate sales, which is positive for shareholders, but the consolidated picture remains weak because the pharma subsidiary is bleeding heavily. Investors should closely track Medgel Private Limited's recovery, as it is the key swing factor for group-level profitability and EPS.